Advanced Enzyme Tech Share Price Today | Stock Price & Advanced Enzyme Tech Share Screener
As of November 18, 2026, the live Advanced Enzyme Tech share price (NSE: ADVENZYMES) is ₹281.00 on NSE and ₹281.10 on BSE, down 0.76% from the previous close, with shares trading between ₹276.50 and ₹284.00 in today's trading session, and a 52-week range of ₹248.35–₹392.10. Track ADVENZYMES company valuation to gauge the company's total market size. Use the Advanced Enzyme Tech stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Advanced Enzyme Tech opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹223 and net income of ₹51, with EBITDA of ₹81, an operating margin of 34.0% and a profit margin of 22.9%.
Advanced Enzyme Tech Share Price Chart
Track the current stock price of Advanced Enzyme Tech with an interactive chart. Analyse ADVENZYMES share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Advanced Enzyme Tech stock quote in one place.
The quote of ₹281.00 sits between the 52-week low of ₹248.35 and the 52-week high of ₹392.10, and the latest session moved -0.76% from the previous close.
Advanced Enzyme Tech Company Profile - Fundamental Screener
Screen Advanced Enzyme Tech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ADVENZYMES shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE837H01020.
Company Details
Classification
Identifiers and Leadership
Advanced Enzyme Tech Balance Sheet Screener
Screen ADVENZYMES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,839, up from ₹1,621 in 2025.
Latest statistics put total assets at ₹1,839 and shareholder funds at ₹1,683, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 1,839 | 1,621 | 1,536 | 1,422 | 1,268 | 1,153 | 979 | 811 | 732 | 589 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 692 | 679 | 650 | 649 | 619 | 601 | 563 | 496 | 491 | 421 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 49 | 56 | 58 | 60 | 67 | 54 | 52 | 41 | 51 | 42 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 1,683 | 1,469 | 1,371 | 1,284 | 1,140 | 1,031 | 867 | 705 | 582 | 485 |
| Share Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves & Surplus | 1,609 | 1,399 | 1,302 | 1,213 | 1,066 | 948 | 817 | 657 | 537 | 442 |
Advanced Enzyme Tech Income Statement Screener - Profit & Revenue Analysis
Screen Advanced Enzyme Tech income statement and profit fundamentals. Analyze ADVENZYMES quarterly results. Advanced Enzyme Tech reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹223 and net profit was ₹51, equal to earnings per unit of ₹4.33, at an operating margin of 34%.
In that period expenses were ₹142, interest cost ₹1 and tax ₹18. The next period listed, 2026-Jun, shows revenue of ₹203 and net profit of ₹39.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 223 | 203 | 211 | 192 | 195 | 195 | 176 | 177 | 156 | 162 | 167 | 175 | 164 | 154 | 150 |
| Expenses | 142 | 139 | 140 | 123 | 125 | 130 | 122 | 114 | 104 | 103 | 118 | 107 | 107 | 103 | 99 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 81 | 64 | 71 | 69 | 70 | 65 | 54 | 63 | 52 | 58 | 50 | 68 | 57 | 51 | 51 |
| Operating Profit % | 34.00% | 28.00% | 31.00% | 29.00% | 33.00% | 30.00% | 27.00% | 33.00% | 29.00% | 33.00% | 26.00% | 33.00% | 33.00% | 30.00% | 29.00% |
| Depreciation | 11 | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 69 | 54 | 60 | 58 | 60 | 55 | 44 | 53 | 42 | 49 | 40 | 59 | 48 | 41 | 42 |
| Tax | 18 | 15 | 15 | 15 | 15 | 15 | 17 | 14 | 9 | 14 | 10 | 16 | 13 | 12 | 10 |
| Net Profit | 51 | 39 | 45 | 43 | 45 | 40 | 27 | 39 | 33 | 35 | 30 | 43 | 35 | 29 | 32 |
| EPS | 4.33 | 3.31 | 3.84 | 3.80 | 3.87 | 3.57 | 2.37 | 3.36 | 2.94 | 3.05 | 2.53 | 3.74 | 3.08 | 2.58 | 2.87 |
Advanced Enzyme Tech Cash Flow Screener - Liquidity Fundamentals
Screen ADVENZYMES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹157, and net cash flow was an inflow of ₹15.
Over the same period, investing activities used ₹72 and financing activities used ₹70.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 157 | 143 | 141 | 140 | 122 | 163 | 141 | 129 | 116 | 107 |
| Investing Activities | -72 | -90 | -65 | -286 | 2 | -27 | -43 | -124 | -60 | -60 |
Financing and Net Cash | ||||||||||
| Financing Activities | -70 | -73 | -59 | -26 | -49 | -26 | -39 | -43 | -2 | -65 |
| Net Cash Flow | 15 | -20 | 17 | -171 | 75 | 109 | 60 | -38 | 54 | -18 |
Advanced Enzyme Tech Shareholding Pattern Screener
See Advanced Enzyme Tech shareholding pattern with promoter, FII, and DII holdings. Check Advanced Enzyme Tech promoter holding and ownership changes for ADVENZYMES on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 43.26%, foreign institutions 25.49%, domestic institutions 5.41% and the public 17.57%, spread across 66,193 shareholders.
The shareholder count was 66,193 in 2026-Mar, compared with 63,599 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 43.26% | 43.24% | 43.56% | 43.08% | 43.08% | 43.07% | 43.04% | 43.49% |
Institutional Investors | ||||||||
| FII Holding | 25.49% | 26.71% | 26.65% | 11.90% | 23.46% | 25.41% | 25.86% | 23.01% |
| DII Holding | 5.41% | 4.78% | 1.89% | 8.19% | 8.45% | 6.41% | 5.51% | 7.56% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 17.57% | 16.94% | 18.65% | 16.68% | 16.92% | 16.95% | 17.44% | 15.43% |
| Other Holding | 8.26% | 8.33% | 9.25% | 20.16% | 8.10% | 8.15% | 8.15% | 10.51% |
| Shareholder Count | 66,193 | 63,599 | 67,468 | 65,322 | 67,589 | 69,637 | 68,051 | 68,640 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Advanced Enzyme Tech. Advanced Enzyme Tech dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹5.35 per unit for 2026-March, a yield of 1.90%, compared with ₹5.20 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹5.35, ₹5.20 and ₹5.10 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹5.35 | 1.90% |
| 2025-March | ₹5.20 | 2.04% |
| 2024-March | ₹5.10 | 1.83% |
| 2023-March | ₹1.00 | 0.29% |
| 2022-March | ₹1.00 | 0.42% |
| 2021-March | ₹0.90 | 0.32% |
| 2020-March | ₹0.60 | 0.17% |
| 2019-March | ₹0.60 | 0.42% |
| 2018-March | ₹0.50 | 0.27% |
| 2017-March | ₹0.40 | 0.19% |
Advanced Enzyme Tech Stock Index Membership - Nifty & Sensex
See which indices include Advanced Enzyme Tech stock. Check ADVENZYMES index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 5 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.
Complete Index List
Advanced Enzyme Tech Market Events Screener - Corporate Actions
Get Advanced Enzyme Tech corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Advanced Enzyme Tech stock events that may affect ADVENZYMES share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 31, 2026, with a record date of October 31, 2026.
It is followed by Quarterly Result Announcement dated August 8, 2026 and Annual General Meeting dated July 31, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-10-31 | 2026-10-31 | Quarterly Result Announcement | NA | 1.82% |
| 2026-08-08 | 2026-08-08 | Quarterly Result Announcement | NA | 2.95% |
| 2026-07-31 | 2026-07-31 | Annual General Meeting | NA | -2.49% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 1.35 /share | -12.04% |
| 2026-05-09 | 2026-05-09 | Quarterly Result Announcement | NA | 2.67% |
| 2026-01-31 | 2026-01-31 | Quarterly Result Announcement | NA | 9.05% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -3.24% |
| 2025-08-02 | 2025-08-02 | Quarterly Result Announcement | NA | 9.08% |
| 2025-07-30 | 2025-07-30 | Annual General Meeting | NA | 17.48% |
| 2025-07-23 | 2025-07-23 | Dividend | ₹ 1.20 /share | 14.47% |
| 2025-05-16 | 2025-05-17 | Dividend | ₹ 4.00 /share | -2.19% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 3.73% |
| 2025-02-08 | 2025-02-08 | Quarterly Result Announcement | NA | 0.59% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | 8.58% |
| 2024-07-25 | 2024-07-25 | Annual General Meeting | NA | -0.83% |
Advanced Enzyme Tech Competitors Screener - Peer Stocks Comparison
Screen ADVENZYMES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,939 | 40.80 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 295,307 | 87.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 176,947 | 85.00 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 125,379 | 89.90 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 120,479 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.80 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,510 | 39.50 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,503 | 47.90 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,240 | 25.80 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 89,647 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Advanced Enzyme Tech Company Announcements - News & Reports Screener
Screen ADVENZYMES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 5, 2026.
The next most recent announcements are dated November 5, 2026 and November 3, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-05 | Corporate Action-Updates on Buy back | - |
| 2026-11-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-03 | Announcement under Regulation 31A (LODR)-(8)(c) Submission of application to Exchange | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-31 | Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement | - |
| 2026-10-31 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-10-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-31 | Announcement under Regulation 31A (LODR)-(8)(b) Outcome of Board Meeting | - |
| 2026-10-31 | Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-31 | Board Meeting Outcome for Outcome Of Board Meeting Held On October 31 2026 | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Closure of Buy Back | - |
| 2026-10-30 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-29 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-26 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-26 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-23 | Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares | - |
| 2026-10-23 | Board Meeting Intimation for The Approval Of Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2026 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹281.00, within a 52-week range of ₹248.35 to ₹392.10. The P/E ratio is 17.40 and the P/B ratio is 1.86, with earnings per unit of ₹15.08. Market capitalisation stands at ₹3,131.13 Cr and the dividend yield is 1.90%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.